Balchem (BCPC) Stock Price
Balchem Price
Over the last 19 years Balchem grew revenue by 13.0% annually, reaching 1.04 B USD. Earnings per share have grown at 13.2% per year over the last 19 years. For Balchem, the net margin of 14.9% is up versus 12.0% a few years ago. At today's price the dividend yield works out to roughly 0.57%. The payout ratio is around 20% of earnings. The dividend has grown at 15.7% per year over the past 19 years. The consensus 12-month price target for Balchem is 215.00 USD, about 28.1% above where the stock trades today. Of 9 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 20% above its 52-week low.
Balchem stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Balchem over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Balchem stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Balchem's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Balchem Price |
|---|---|
| 9/24/2026 | 167.84 USD |
| 9/23/2026 | 168.24 USD |
| 9/22/2026 | 169.02 USD |
| 9/21/2026 | 167.50 USD |
| 9/18/2026 | 164.68 USD |
| 9/17/2026 | 165.76 USD |
| 9/16/2026 | 168.59 USD |
| 9/15/2026 | 165.00 USD |
| 9/14/2026 | 167.71 USD |
| 9/11/2026 | 165.45 USD |
| 9/10/2026 | 166.67 USD |
| 9/9/2026 | 168.34 USD |
| 9/8/2026 | 169.46 USD |
| 9/4/2026 | 171.61 USD |
| 9/3/2026 | 171.74 USD |
| 9/2/2026 | 175.47 USD |
| 9/1/2026 | 173.31 USD |
| 8/31/2026 | 175.89 USD |
| 8/30/2026 | 175.28 USD |
| 8/28/2026 | 177.93 USD |
| 8/27/2026 | 178.77 USD |
| 8/26/2026 | 179.79 USD |
| 8/25/2026 | 179.50 USD |
| 8/24/2026 | 180.38 USD |
| 8/21/2026 | 181.28 USD |
| 8/20/2026 | 179.63 USD |
| 8/19/2026 | 180.95 USD |
| 8/18/2026 | 178.09 USD |
| 8/14/2026 | 178.51 USD |
| 8/13/2026 | 177.14 USD |
Balchem Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Balchem Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.54 | 0.55 | 0.55 | 0.59 | 0.64 | 0.64 | 0.70 | 0.80 | 0.94 | 0.92 | 0.95 | 1.04 | 1.13 | 1.20 | 1.26 | 1.32 |
| 60.53 | 2.03 | 0.18 | 7.41 | 8.25 | – | 9.33 | 13.66 | 17.90 | -2.12 | 3.36 | 8.81 | 9.06 | 5.66 | 5.36 | 4.92 |
| 26.62 | 30.43 | 32.55 | 31.82 | 31.73 | 32.81 | 31.72 | 30.41 | 29.72 | 32.75 | 35.26 | 35.68 | 35.68 | 35.68 | 35.68 | 35.68 |
| 144.00 | 168.00 | 180.00 | 189.00 | 204.00 | 211.00 | 223.00 | 243.00 | 280.00 | 302.00 | 336.00 | 370.00 | 403.54 | 426.37 | 449.21 | 471.33 |
| 82.00 | 93.00 | 90.00 | 96.00 | 106.00 | 102.00 | 111.00 | 127.00 | 145.00 | 159.00 | 182.00 | 218.00 | 242.00 | 252.00 | 326.00 | 342.00 |
| 15.16 | 16.85 | 16.27 | 16.16 | 16.49 | 15.86 | 15.79 | 15.89 | 15.39 | 17.25 | 19.10 | 21.02 | 21.40 | 21.09 | 25.89 | 25.89 |
| 52.00 | 59.00 | 55.00 | 90.00 | 78.00 | 79.00 | 84.00 | 96.00 | 105.00 | 108.00 | 128.00 | 154.00 | 176.00 | 183.00 | – | – |
| 18.18 | 13.46 | -6.78 | 63.64 | -13.33 | 1.28 | 6.33 | 14.29 | 9.38 | 2.86 | 18.52 | 20.31 | 14.29 | 3.98 | – | – |
| 0.60 | 0.34 | 0.76 | 0.42 | 0.47 | 0.52 | 0.58 | 0.64 | 0.71 | 0.79 | 0.87 | 0.96 | 1.06 | 1.17 | 1.30 | – |
| 130.77 | -43.33 | 123.53 | -44.74 | 11.90 | 10.64 | 11.54 | 10.34 | 10.94 | 11.27 | 10.13 | 10.34 | 10.42 | 10.38 | 11.11 | – |
| 31.39 | 31.82 | 32.07 | 32.31 | 32.48 | 32.45 | 32.53 | 32.72 | 32.40 | 32.48 | 32.55 | 32.32 | 32.32 | 32.32 | 32.32 | 32.32 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Balchem generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Balchem retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Balchem's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Balchem has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Balchem's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Balchem stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Balchem Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Balchem business model & stock analysis
Balchem SWOT Analysis
Strengths
Balchem Corp has several key strengths that contribute to its success in the market. Firstly, the company has a strong reputation for producing high-quality products, particularly in the food and pharmaceutical industries. This reliability has built trust with customers and allowed the company to maintain long-term partnerships.
Secondly, Balchem Corp has developed a diverse product portfolio, offering a range of specialty chemicals, ingredients, and nutritional products. This diversity helps the company mitigate risks associated with dependence on a single product or industry.
Furthermore, the company has a robust research and development department, which enables continuous innovation and adaptation to changing market demands. This focus on technology and product development gives Balchem Corp a competitive edge.
Weaknesses
Despite its strengths, Balchem Corp also faces several weaknesses that could hinder its growth prospects. Firstly, the company may be vulnerable to changes in raw material prices, as the cost of ingredients could impact profit margins. This risk requires effective supply chain management and hedging strategies.
Additionally, Balchem Corp's strong focus on research and development may lead to high operating expenses. While this investment in innovation is necessary for the company's growth, it also puts pressure on profitability and requires efficient cost management.
Lastly, Balchem Corp may struggle with brand awareness in certain markets. As the company looks to expand globally, establishing brand recognition and trust among new consumers may pose a challenge and require strategic marketing efforts.
Opportunities
Several opportunities exist for Balchem Corp to further capitalize on its strengths and expand its market presence. Firstly, the growing demand for health and wellness products provides a chance for the company to leverage its expertise in nutritional solutions and target new customer segments.
Moreover, Balchem Corp could explore strategic partnerships or acquisitions to enhance its product offerings and enter new markets. Collaborations with established players or the acquisition of complementary businesses would provide synergistic benefits and accelerate growth.
Furthermore, expansion into emerging economies presents an opportunity for Balchem Corp, as these markets often have increasing disposable incomes and a rising demand for specialty chemical and ingredient solutions.
Threats
Balchem Corp must also be wary of potential threats that could impact its business operations. Firstly, intense competition within the industry could erode market share and pricing power. The company needs to continuously monitor competitors' strategies and differentiate its products to maintain a competitive edge.
Additionally, regulatory changes and compliance requirements can present challenges, particularly in the food and pharmaceutical industries where Balchem Corp operates. Adapting to evolving regulations and ensuring adherence is crucial to avoid penalties or reputational damage.
Lastly, economic downturns and fluctuations in the global economy could negatively impact demand for Balchem Corp's products. Maintaining a resilient financial position and diversifying its customer base across industries and geographic regions can help mitigate this threat.
Balchem Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Balchem Segments
Balchem Revenue by Segment (1/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Balchem Revenue by Segment (2/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Balchem Revenue by Segment (3/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Balchem Revenue by Segment (4/5)
3 Years
5 Years
10 Years
Max
Details
Balchem Revenue by Segment (5/5)
3 Years
5 Years
Max
Details
Balchem Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Balchem Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Balchem historical P/E ratio, EBIT multiple, and P/S ratio
Balchem annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Balchem's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Balchem's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Balchem's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Balchem shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Balchem stock splits
Since 1990, a total of 18.984375 shares have been converted from one Balchem share.
Balchem Dividend History
35 years of dividend payments · 8 consecutive increases
Balchem dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Balchem dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Balchem forecasts and price targets in September 2026
Analyst Price Targets 2026Balchem Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/3/2026 | Maintained | Buy | – | |
| 5/4/2026 | Maintained | Buy | – | |
| 2/24/2026 | Maintained | Buy | – | |
| 10/22/2025 | Maintained | Buy | – | |
| 8/4/2025 | Maintained | Buy | – | |
| 4/28/2025 | Maintained | Buy | – | |
| 2/24/2025 | Maintained | Buy | – | |
| 11/4/2024 | Maintained | Buy | – | |
| 7/31/2024 | Maintained | Buy | – | |
| 5/6/2024 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Balchem Earnings Calls
Balchem Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 10/20/2026 | 1.43USD | - | 289.25 MUSD | - | 2026 Q3 |
| 7/31/2026 | 1.27USD | 1.40USD | 268.50 MUSD | - | 2026 Q2 |
| 4/30/2026 | 1.33USD | 1.25USD | 266.50 MUSD | - | 2026 Q1 |
| 2/20/2026 | 1.29USD | 1.31USD | 259.59 MUSD | - | 2025 Q4 |
| 10/21/2025 | 1.36USD | 1.35USD | 259.59 MUSD | - | 2025 Q3 |
| 7/31/2025 | 1.25USD | 1.27USD | 257.65 MUSD | - | 2025 Q2 |
| 4/24/2025 | 1.25USD | 1.22USD | 245.70 MUSD | - | 2025 Q1 |
| 2/21/2025 | 1.11USD | 1.03USD | 244.91 MUSD | - | 2024 Q4 |
| 10/25/2024 | 1.11USD | 1.13USD | 235.08 MUSD | - | 2024 Q3 |
| 7/26/2024 | 1.03USD | 1.09USD | 239.69 MUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Balchem stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Balchem shareholder structure
| % | Name |
|---|---|
14.84970% | |
13.56210% | |
11.86531% | |
6.72745% | |
4.39237% | |
4.36580% |
Balchem Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
15.00% | SEC ↗ | |
15.00% | SEC ↗ | |
14.40% | SEC ↗ | |
11.56% | SEC ↗ | |
8.40% | SEC ↗ | |
8.40% | SEC ↗ | |
8.40% | SEC ↗ | |
8.40% | SEC ↗ | |
8.40% | SEC ↗ | |
6.93% | SEC ↗ |
Balchem Executives and Management Board
12 members · avg. age 58 · 25 % women
Mr. Theodore Harris (60)
Chairman of the Board, President, Chief Executive Officer · since 2015
6.87 M USD
Management
Mr. C. Martin Bengtsson (47)
Chief Financial Officer, Executive Vice President
Mr. Frederic Boned (46)
Senior Vice President, General Manager - Human Nutrition and Health
Ms. Hatsuki Miyata (48)
Executive Vice President, Chief Legal Officer and Secretary
Mr. Martin Reid (57)
Senior Vice President and Chief Supply Chain Officer
Mr. William Backus (58)
Chief Accounting Officer, Vice President
Board of Directors
Mr. Matthew Wineinger (58)
Lead Independent Director
Mr. Daniel Knutson (68)
Independent Director
Ms. Kathleen Fish (67)
Independent Director
Mr. David Fischer (62)
Independent Director
Mr. Olivier Rigaud (60)
Independent Director
Ms. Monica Vicente (59)
Independent Director
Balchem Supply Chain
Balchem Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.69 | 0.32 | 0.75 |
Frequently asked questions about Balchem
Balchem Corp is a leading company with a unique business model. The company specializes in the development, manufacturing, and marketing of specialty performance ingredients and products, catering to various industries. Balchem Corp focuses on providing innovative solutions that enhance the health and well-being of people, animals, and plants. With a diverse portfolio, the company offers nutritional, flavor, and fragrance ingredients, as well as animal health products and specialty film solutions. Balchem Corp consistently aims to deliver high-quality products and services that meet the evolving needs of its customers, reinforcing its position as a trusted industry leader.
Balchem Corp is primarily active in the industries of nutrition and health, animal nutrition, specialty products, and industrial products.
The main competitors of Balchem Corp in the market include companies such as Archer Daniels Midland Company, Innophos Holdings Inc., and Corbion N.V.
Balchem Corp is a leading company in the specialty chemicals industry. Founded in 1967, Balchem Corp has established a strong reputation for delivering innovative solutions across various sectors including human and animal nutrition, food and beverage, and pharmaceuticals. The company's rich history spans over five decades, marked by continuous growth and strategic acquisitions. Balchem Corp remains committed to providing high-quality products and services, leveraging its expertise in encapsulation, chelation, and controlled release technologies. With a customer-centric approach and a focus on sustainable solutions, Balchem Corp continues to drive forward in its mission to enhance health and well-being through its diverse portfolio of products and cutting-edge research.
Balchem Corp has achieved several significant milestones in its history. One of the key milestones is its acquisition of certain assets of Animal Nutrition & Health (ANH) business from a leading global food company, AkzoNobel, in 2012. This acquisition allowed Balchem to expand its portfolio and become a leading provider of encapsulated nutraceuticals for both human and animal health markets. Additionally, the company has consistently demonstrated strong financial performance over the years, with increasing revenues and earnings. Furthermore, Balchem has established itself as a trusted name in the industry, known for its high-quality products and innovative solutions.
Balchem Corp is primarily present in the United States.
Balchem Corp represents a commitment to innovation, sustainability, and to making a positive impact in the industries it serves. The company focuses on delivering high-quality, science-based solutions that provide unique value to its customers. Balchem Corp places a strong emphasis on corporate responsibility, striving to operate in a socially and environmentally responsible manner. With a dedicated team and a customer-centric approach, the company aims to consistently provide exceptional products and services that meet the evolving needs of its clients.
Analysts currently set an average price target of 215.00 USD for the Balchem stock (median: 215.00 USD), implying +27.8 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Balchem stock: 7 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Balchem to generate revenue of 1.13 B USD and earnings per share of 5.45 USD.
Converted at the current exchange rate, the Balchem share trades at 147.48 EUR (167.84 USD).
The Balchem share (BCPC) is listed on 5 stock exchanges, including: NASDAQ (BCPC), SIX (Zürich) (BL9B.SW), Frankfurt (BL9B.F), München (BL9B.MU), Düsseldorf (BL9B.DU).
Balchem Corp is a leading company in the fields of animal nutrition, human nutrition, and industrial chemicals. The innovative company offers a wide range of products and solutions tailored to the needs of its customers. Balchem's animal nutrition division provides solutions for animal feed enhancement, health, and well-being of livestock, pets, and aquaculture. Balchem's products help animal owners improve the health of their animals and increase growth and productivity. Balchem uses innovative technologies to offer its customers powerful and effective feed enhancement solutions that provide significant benefits for animal health and performance. Balchem's human nutrition division offers solutions tailored to the health and needs of the modern consumer. Balchem's products include functional ingredients, vitamins, minerals, and amino acids used in food, beverages, supplements, and pharmaceutical products. Balchem aims to improve human health and well-being by offering innovative products that help consumers maximize their health and happiness. Balchem's industrial chemicals division offers a variety of solutions for applications in agriculture, industry, and other industries. Balchem produces and distributes chemicals that can be used for many different purposes, including pesticides, defoliants, flame retardants, and many more. Balchem leverages its experience and expertise in the chemical industry to offer innovative solutions to its customers, helping them achieve their business goals. An example of a Balchem product is Choline Chloride, which is known as an essential nutrient for animals. It supports the growth and maintenance of cells and tissues, especially the nervous system. It is necessary for the synthesis of lecithin, which is an important component of any cell membrane. Overall, Balchem's business model is based on providing innovative, customer-oriented solutions tailored to the needs of its customers. The company has a strong focus on research and development of new products and technologies, which allows it to continuously enter new markets and remain competitive. By continuously evolving high-quality products and services, Balchem creates value for its customers and supports them in achieving their goals.
The expected revenue of Balchem is 1.13 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Balchem is 176.17 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Balchem is currently 30.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Balchem stock.
The price-to-sales ratio (P/S) of Balchem is currently 4.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Balchem stock.
The Eulerpool Quality Score for Balchem is 6/10.
The ISIN of Balchem is US0576652004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Balchem is 905650. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Balchem is BCPC. The ticker symbol is used to trade Balchem shares on the stock exchange.
Over the past 12 months, Balchem paid a dividend of 0.96 USD . This corresponds to a dividend yield of about 0.57 %. For the coming 12 months, Balchem is expected to pay a dividend of 1.17 USD.
The current dividend yield of Balchem is 0.57 %.
Balchem pays a dividend, distributed in the months of December.
Balchem paid dividends every year for the past 35 years.
For the upcoming 12 months, dividends amounting to 1.17 USD are expected. This corresponds to a dividend yield of 0.70 %.
Balchem is assigned to the 'Commodities' sector.
To receive the latest dividend of Balchem from 1/20/2026 amounting to 0.96 USD, you needed to have the stock in your portfolio before the ex-date on 12/23/2025.
The last dividend was paid out on 1/20/2026.
In the year 2025, Balchem distributed 0.96 USD as dividends.
The dividends of Balchem are distributed in USD.
Balchem stock
Balchem Peer Group
Balchem Ticker
Balchem FIGI
All fundamentals and in-depth analysis of Balchem
Our stock analysis for Balchem stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Balchem. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.